Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection.

OBJECTIVE

In this study, we aimed to evaluate mir-31-5p as a prognostic biomarker of keloid disease (KD) recurrence using a retrospective, treatment naïve, surgical cohort of head and neck KD cases from Henry Ford Health.

METHODS

Using a tissue microarray, mir-31-5p expression was measured with miRNAscope, and mir-31-5p cell positivity was determined with QuPath. Logistic regression was used to test the association between mir-31-5p positive cells and KD recurrence at 1 year. In an independent dataset, associations between mir-31-5p and messenger RNA (mRNA) expression were assessed. Ingenuity Pathway Analysis identified target genes and pathways impacted by mir-31-5p.

RESULTS

Of the 58 KD patients, 42 (72%) received adjuvant triamcinolone injections, and 8 recurred (14%). mir-31-5p was expressed in 48 (83%) specimens. Increasing mir-31-5p expression was associated with decreased risk of recurrence ( = .031), with an odds ratio of 0.86 (95% CI 0.75-0.98) for each 20% increase in mir-31-5p cellular positivity. This effect persisted with triamcinolone treatment (odds ratio 0.82; 95% CI 0.71-0.95;  = .015). mir-31-5p correlated with gene expression enriched in KD pathways, including mRNA splicing and autophagy.

CONCLUSION

Taken together, our data supports the association between mir-31-5p expression and KD recurrence. Its potential as a prognostic biomarker should be further investigated.

LEVEL OF EVIDENCE

Level 2.